Climb Bio, Inc. current report, 16 May 2022

Full document

Filing Overview

This Form 8-K was filed by Eliem Therapeutics, Inc. on May 16, 2022, under Item 2.02 and Item 9.01. It reports the issuance of a press release announcing financial results for the quarter ended March 31, 2022. The provided filing text does not include the press release or the underlying financial results.

The request metadata identifies the company as Climb Bio, Inc.; however, the filing identifies the registrant as Eliem Therapeutics, Inc. and lists common stock trading under the symbol ELYM on Nasdaq.

Financial Results and Liquidity

  • Quarter: ended March 31, 2022.
  • Revenue, net loss or profit, operating expenses, cash flow, cash balance, debt, liquidity, margins, and other financial metrics: the filing text does not provide clear values.
  • No balance sheet, income statement, cash flow statement, or detailed financial tables are included in the provided text.

Changes Versus Prior Period

The filing states that quarterly financial results were announced but does not provide the results or comparable prior-period figures. Material changes versus the prior comparable period therefore cannot be determined from the provided text.

Guidance, Outlook, Risks, and Unusual Items

  • No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are described in the filing text provided.
  • The referenced press release, filed as Exhibit 99.1 for furnishing purposes, may contain additional financial and operating information, but its contents are not included.
  • The company qualifies as an emerging growth company.

Investor Verification Items

  1. Obtain and review Exhibit 99.1 for the actual quarterly financial results and management commentary.
  2. Verify cash, cash runway, operating expenses, net loss, and financing or liquidity disclosures for the quarter ended March 31, 2022.
  3. Confirm the registrant identity, since the filing names Eliem Therapeutics, Inc., while the request metadata names Climb Bio, Inc.
  4. Check for any guidance, pipeline updates, or risk disclosures contained in the referenced press release.